PMID: 9435873Jan 22, 1998Paper

CD3 x CD19 bispecific antibodies and CD28 costimulation for locoregional treatment of low-malignancy non-Hodgkin's lymphoma

Cancer Immunology, Immunotherapy : CII
O ManzkeH Bohlen

Abstract

In advance of using bispecific antibodies for the treatment of B cell lymphoma in humans, we analysed CD3 x CD19 bispecific antibodies for their capacity to induce T cell activation in cell suspensions from follicular lymphoma lymph nodes. Here, we demonstrate that the lack of costimulatory molecules, such as members of the B7 family, on the tumour cells resulted in insufficient activation of autologous T lymphocytes. However, stimulation and proliferation of T cells could be induced by addition of monospecific CD28 antibodies. Moreover, we show that bispecific CD3 x CD19 antibodies can protect severe combined immunodeficiency (SCID) mice from human Epstein-Barr-virus (EBV)-induced B cell lymphoma growth. In these in vivo studies, CD28 costimulation did not show a significant benefit, possibly because of the high-level expression of CD80 and CD86 on the surface of the lymphoma cells. Furthermore, the treatment of SCID mice with bispecific antibodies, with or without CD28 antibodies, induced tumour-protective effects, as determined by a rechallenging experiment in long-term-surviving animals with the autologous EBV-transformed tumour B cell line. Treatment of a follicular lymphoma patient by intratumoural injection of both antib...Continue Reading

Citations

May 10, 2007·Cancer Immunology, Immunotherapy : CII·Freddy Tita-NwaMartin Kornacker
Jun 6, 2000·Advanced Drug Delivery Reviews· de Leij LB J Kroesen
Aug 1, 2008·Protein Expression and Purification·Fang LiuZhenping Zhu
Nov 5, 2014·Immunology and Cell Biology·Amelia M HuehlsCharles L Sentman
Jun 22, 2002·The Journal of Immunology : Official Journal of the American Association of Immunologists·Sergey M KipriyanovMelvyn Little
Dec 26, 2015·Antibodies·Joanie Del BanoBrigitte Kerfelec

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

Antibody Engineering

Antibody engineering technologies are constantly advancing to improve the clinical effectiveness of monoclonal and bispecific antibodies. Discover the latest research on Antibody Engineering here.

Cancer Biology: Molecular Imaging

Molecular imaging enables noninvasive imaging of key molecules that are crucial to tumor biology. Discover the latest research in molecular imaging in cancer biology in this feed.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.